SCHEMBL19472153

SCHEMBL19472153

O=c1oc2ccccc2c2ccc(-n3c4ccccc4c4cc5c6ccccc6n(-c6ccccc6)c5cc43)cc12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.45
KDM4E B2RXH2 2/20 0.45
ATM Q13315 1/20 0.45
CA9 Q16790 4/20 0.41
NPSR1 Q6W5P4 3/20 0.40
RXFP1 Q9HBX9 3/20 0.40
CA12 O43570 2/20 0.38
ALDH1A1 P00352 5/20 0.38
KMT2A Q03164 3/20 0.38
MEN1 O00255 1/20 0.38
POLB P06746 1/20 0.38
TSHR P16473 1/20 0.38
BRCA1 P38398 1/20 0.38
HSD17B10 Q99714 1/20 0.38
MAPT P10636 3/20 0.37
LMNA P02545 2/20 0.37
MAPK1 P28482 2/20 0.37
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19472214 0.96 L3MBTL1 (0.46) L3MBTL1KDM4EATMCA9NPSR1
SCHEMBL16925911 0.93 KDM4E (0.45) L3MBTL1KDM4EATMCA9NPSR1
SCHEMBL16925832 0.93 KDM4E (0.45) L3MBTL1KDM4EATMCA9NPSR1
SCHEMBL16925863 0.92 NPSR1 (0.41) L3MBTL1KDM4EATMCA9NPSR1
SCHEMBL19472152 0.91 NPSR1 (0.47) L3MBTL1KDM4EATMCA9NPSR1
SCHEMBL19472154 0.91 KMT2A (0.47) L3MBTL1KDM4EATMCA9NPSR1
SCHEMBL19472202 0.90 L3MBTL1 (0.43) L3MBTL1KDM4EATMCA9NPSR1
SCHEMBL17637916 0.90 NPSR1 (0.43) L3MBTL1KDM4ENPSR1RXFP1ALDH1A1
SCHEMBL16925907 0.90 KDM4E (0.50) L3MBTL1KDM4EATMCA9NPSR1
SCHEMBL16925777 0.90 KDM4E (0.50) L3MBTL1KDM4EATMCA9NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3197887-B1 HETEROCYCLIC COMPOUNDS WITH BENZO[C]COUMARIN-STRUCTURES MERCK PATENT GMBH (DE) 2020-09-23 EP disclosed
US-10377766-B2 Heterocyclic compounds with benzo(c)coumarin-structures MERCK PATENT GMBH (DE) 2019-08-13 US disclosed
US-20170298077-A1 HETEROCYCLIC COMPOUNDS WITH BENZO(C)COUMARIN-STRUCTURES MERCK PATENT GMBH (DE) 2017-10-19 US disclosed
US-20170298077-A1 HETEROCYCLIC COMPOUNDS WITH BENZO(C)COUMARIN-STRUCTURES MERCK PATENT GMBH (DE) 2017-10-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170298077-A1 HETEROCYCLIC COMPOUNDS WITH BENZO(C)COUMARIN-STRUCTURES NISCH, SIRT3, NQO1 L3MBTL1 3462/4885KDM4E 2837/4885ATM 3283/4885
US-10377766-B2 Heterocyclic compounds with benzo(c)coumarin-structures NISCH, SIRT3, NQO1 L3MBTL1 3462/4885KDM4E 2837/4885ATM 3283/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.